Patients on a perioperative Keytruda regimen saw a 30 percent reduction in the risk of recurrence, progression, or death versus the control arm.
The financing will allow the company to build commercial-grade manufacturing capabilities and make regulatory preparations in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback